The International Neuromodulation Society

The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.

The INS Peer-Reviewed Journal – 8 Issues a Year

The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online. The journal also has social media accounts on Twitter, Facebook, and Instagram.

journal cover

+Submit a Manuscript.+


What is Neuromodulation?

Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:

If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

Members may log in and visit the members-only section’s Global Discussion Forum

Breaking News Share

Deep Brain Stimulation System Receives FDA Approval for an Additional Brain Target in Parkinson's Disease

Jan. 24, 2020 - Abbott announced the FDA has approved using its deep brain stimulation system to target the globus pallidus interna to manage medication-resistant motor symptoms of Parkinson's disease. (Source: MD+DI)

Study Results Presented Concerning Spinal Cord Stimulation in Chronic Pain

Jan. 23, 2020 - Abbott announced results presented at the North American Neuromodulation Society annual meeting about two prospective studies of its spinal cord stimulation system in people in chronic pain. (Biospace)

Device Maker Announces Scientific Presentations Concerning Its Spinal Cord Stimulation System

Jan. 22, 2020 - Nevro Corp. announced there will be a series of data presentations at the North American Neuromodulation Society annual meeting this week in Las Vegas concerning the company's spinal cord stimulation system for chronic pain. (Source: PR Newswire)

Company Begins Proof-of-Concept Studies in Human Subjects

Jan. 22, 2020 - Soin Neuroscience announced the start of early stage proof-of-concept studies in human subjects for the spinal cord stimulation device that the company is developing for chronic pain. (Source: P&T Community)

Company Announces Presentation of Spinal Cord Stimulation Studies

Jan. 21, 2020 - Saluda Medical Pty Limited announced that multiple studies of its spinal cord stimulation system for treatment of chronic pain will be presented during the annual meeting of the North American Neuromodulation Society. Neurology Advisor also published a summary of recent findings. (Source: PR Newswire)

Three-month Results Released from Randomized Controlled Trial Comparing Spinal Cord Stimulation Modes

Jan. 21, 2020 - Medtronic plc announced three-month results from a randomized controlled trial of differential target multiplexed spinal cord stimulation (SCS) compared to conventional SCS, adding that the results will be presented at the annual meeting of the North American Neuromodulation Society. (Source: Globe Newswire)

Case Series Published Concerning Peripheral Nerve Stimulation in Low Back Pain

Jan. 21, 2020 - SBR Therapeutics announced publication of a prospective case series concerning its peripheral nerve stimulation system in the treatment of low back pain. (Source: NeuroNews)

To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.

Continue Reading News Briefs


International Neuromodulation Society 3rd Interim Meeting, Oct. 23-25, 2020, Mumbai, India:

IM-INS2020-poster
Last Updated on Monday, December 12, 2016 10:01 AM